Shattuck Labs to Report Second Quarter 2021 Financial Results and Provide Corporate Update on August 11, 2021

$STTK
Biotechnology: Pharmaceutical Preparations
Health Care
Get the next $STTK alert in real time by email

AUSTIN, TX and DURHAM, NC, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ:STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, will host a webcast and conference call to provide a corporate and financial update for the second quarter of 2021 on Wednesday, August 11, 2021, at 4:30 p.m. ET.

The live call may be accessed by dialing (833) 614-1555 (domestic) or (516) 575-8754 (international) and entering the conference code: 7172288. The live and archived webcast will be available on the Events & Presentations section of the Company's website. A replay of the webcast will be archived for up to 90 days following the presentation date.

About Shattuck Labs, Inc.

Shattuck is a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease. Compounds derived from Shattuck's proprietary Agonist Redirected Checkpoint, ARC®, platform simultaneously inhibit checkpoint molecules and activate costimulatory molecules within a single therapeutic. The company's lead wholly owned program, SL-172154 (SIRPα-Fc-CD40L), which is designed to block the CD47 immune checkpoint and simultaneously agonize the CD40 pathway, is being evaluated in a Phase 1 trial. A second compound, SL-279252 (PD1-Fc-OX40L), is being evaluated in a Phase 1 trial in collaboration with Takeda Pharmaceuticals. Additionally, the company is advancing a proprietary Gamma Delta T Cell Engager, GADLEN™, platform, which is designed to bridge gamma delta T cells to tumor antigens for the treatment of patients with cancer. Shattuck has offices in both Austin, Texas and Durham, North Carolina. For more information, please visit: www.ShattuckLabs.com.

The Company intends to use the investor relations portion of its website as a means of disclosing material non-public information and for complying with disclosure obligations under Regulation FD.

Investor Contact:

Conor Richardson

Senior Director, Finance & Investor Relations

Shattuck Labs, Inc.

InvestorRelations@shattucklabs.com

Media Contact:

Stephanie Ascher

Managing Director

Stern Investor Relations, Inc.

Stephanie.Ascher@sternir.com



Primary Logo

Get the next $STTK alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$STTK

DatePrice TargetRatingAnalyst
10/2/2024$8.00 → $2.00Buy → Neutral
Citigroup
10/2/2024Buy → Hold
Needham
10/1/2024Buy → Neutral
H.C. Wainwright
6/17/2024Buy → Neutral
BTIG Research
8/31/2022$12.00Buy
BTIG Research
6/1/2022$13.00Buy
Citigroup
5/2/2022$28.00Buy
H.C. Wainwright
More analyst ratings

$STTK
Press Releases

Fastest customizable press release news feed in the world

See more
  • Shattuck Labs Announces Oral Presentation at Upcoming 20th Congress of European Crohn's and Colitis Organization (ECCO) in Inflammatory Bowel Diseases 2025

    AUSTIN, TX & DURHAM, NC, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ:STTK), a biotechnology company pioneering the development of novel therapeutics targeting tumor necrosis factor (TNF) superfamily receptors for the treatment of patients with inflammatory and immune-related diseases, today announced an upcoming oral presentation at the 20th Congress of ECCO in Inflammatory Bowel Diseases 2025 being held in Berlin, Germany from February 19–22, 2025. This presentation will feature results from the IND-enabling toxicology studies of SL-325, a first-in-class DR3 blocking antibody, in non-human primates. Presentation Details: Title: Pre-Clinical Development of SL

    $STTK
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Shattuck Labs Announces Poster Presentation at Upcoming 2025 Crohn's and Colitis Congress

    AUSTIN, TX and DURHAM, NC, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ:STTK), a biotechnology company pioneering the development of novel therapeutics targeting tumor necrosis factor (TNF) superfamily receptors for the treatment of patients with inflammatory and immune-related diseases, today announced an upcoming poster presentation at the 2025 Crohn's and Colitis Congress being held in San Francisco, California from February 6–8, 2025. Presentation DetailsFormat: Poster presentationTitle: Development and Characterization of SL-325, a DR3-Targeted, Antagonistic Antibody for the Treatment of IBDPresenter: Suresh de Silva, Ph.D., Shattuck's Co-Chief Scientific

    $STTK
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Shattuck Labs Announces Presentation at the 43rd Annual J.P. Morgan Healthcare Conference

    AUSTIN, TX and DURHAM, NC, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ:STTK), a biotechnology company pioneering the development of novel therapeutics targeting tumor necrosis factor (TNF) superfamily receptors for the treatment of patients with inflammatory and immune-related diseases, today announced that company management will present a corporate update and participate in one-on-one meetings at the 43rd Annual J.P. Morgan Healthcare Conference being held in San Francisco, California on January 13-16, 2025. Conference DetailsFormat: Presentation and one-on-one meetingsPresenter: Dr. Taylor Schreiber, M.D., Ph.D., Shattuck's Chief Executive OfficerDate: Janu

    $STTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

$STTK
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$STTK
Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

See more

$STTK
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$STTK
SEC Filings

See more

$STTK
Leadership Updates

Live Leadership Updates

See more
  • Shattuck Labs Announces Appointment of Clay Siegall, Ph.D., and Kate Sasser, Ph.D., to its Board of Directors

    AUSTIN, TX and DURHAM, NC, March 04, 2024 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ:STTK), a clinical-stage biotechnology company pioneering the development of bifunctional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced the appointment of Clay Siegall, Ph.D., and Kate Sasser, Ph.D., to its Board of Directors, effective March 1, 2024. Both Dr. Siegall and Dr. Sasser are highly successful executives and scientific pioneers who bring valuable industry experience to Shattuck. "It is a pleasure to welcome Clay and Kate, esteemed industry leaders, to our Board of Directors," said Taylor Schre

    $IMNM
    $STTK
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Shattuck Labs to Report Third-Quarter 2023 Financial Results on November 9, 2023

    AUSTIN, TX and DURHAM, NC, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ:STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced it will report its third-quarter 2023 financial results and provide a general business overview on Thursday, November 9, 2023. Title: Shattuck Labs Third-Quarter 2023 Earnings Call Speakers: Taylor Schreiber, CEO; Andrew Neill, CFO; Lini Pandite, CMO Date & Time: Thursday, November 9, 2023 at 8:00 a.m. ET Dial-in Details: Toll-Free Dial-In Number: 1 (888) 440-4368 To

    $STTK
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Shattuck Labs Announces Changes to its Board of Directors

    AUSTIN, TX and DURHAM, NC, Oct. 28, 2021 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ:STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease with three ongoing Phase 1 clinical trials, today announced the appointment of Dr. Carrie Brownstein, M.D., to its Board of Directors. Dr. Brownstein currently serves as the Chief Medical Officer at Cellectis. She will replace Josiah Hornblower, Shattuck's Chairman and founder, who is stepping down from the Board of Directors. George Golumbeski, Ph.D., has been appointed Chairman of the

    $STTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

$STTK
Financials

Live finance-specific insights

See more

$STTK
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more